Swiss pharma giant Roche (ROG: SIX) says that, in the first three months of 2023, group sales declined by 3% (-7% in Swiss franc term) to 15.3 billion francs ($17.2 billion).
However, the company noted that the appreciation of the Swiss franc against most currencies had a negative impact on the results reported in Swiss francs compared to constant exchange rates. Roche’s shares dipped 1.4% following the announcement.
As expected, the first quarter 2023 results reflected the exceptionally high demand for COVID-19 tests in the same quarter of 2022, when the Omicron wave was at its peak.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze